Efficacy and safety of domestic and brand name bortezomib in the treatment of newly diagnosed multiple myeloma.
10.3760/cma.j.issn.0253-2727.2020.03.015
- Author:
Hui Min SUN
1
;
Zhong Xing JIANG
2
;
Wei Min WANG
2
;
Shu Juan WANG
2
;
Fang Fang GE
2
;
Jing Dong LI
3
;
Hong Mian ZHAO
4
Author Information
1. Henan Provincial People's Hospital, International Medical Center of Henan, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou 450000, China.
2. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
3. Department of Hematology, The First Affiliated Hospital of Xinxiang Medical College, Weihui 453100, China.
4. Department of Hematology, Huaihe Hospital of Henan University, Kaifeng 475000, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Bortezomib/therapeutic use*;
Dexamethasone;
Humans;
Multiple Myeloma/drug therapy*;
Treatment Outcome
- From:
Chinese Journal of Hematology
2020;41(3):261-263
- CountryChina
- Language:Chinese
